Cargando…
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
AIM: To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes. METHODS: We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomize...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490461/ https://www.ncbi.nlm.nih.gov/pubmed/28663934 http://dx.doi.org/10.7717/peerj.3405 |
_version_ | 1783246988240748544 |
---|---|
author | Xu, Lubin Li, Yang Lang, Jiaxin Xia, Peng Zhao, Xinyu Wang, Li Yu, Yang Chen, Limeng |
author_facet | Xu, Lubin Li, Yang Lang, Jiaxin Xia, Peng Zhao, Xinyu Wang, Li Yu, Yang Chen, Limeng |
author_sort | Xu, Lubin |
collection | PubMed |
description | AIM: To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes. METHODS: We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model. RESULTS: Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), −0.33 ml/min per 1.73 m(2), 95% CI [−0.90 to 0.23]) or in patients with chronic kidney disease (CKD) (WMD −0.78 ml/min per 1.73 m(2), 95% CI [−2.52 to 0.97]). SGLT2 inhibition was associated with eGFR reduction in short-term trials (WMD −0.98 ml/min per 1.73 m(2), 95% CI [−1.42 to −0.54]), and with eGFR preservation in long-term trials (WMD 2.01 ml/min per 1.73 m(2), 95% CI [0.86 to 3.16]). Urine ACR reduction after SGLT2 inhibition was not statistically significant in type 2 diabetic patients in general (WMD −7.24 mg/g, 95% CI [−15.54 to 1.06]), but was significant in patients with CKD (WMD −107.35 mg/g, 95% CI [−192.53 to −22.18]). CONCLUSIONS: SGLT2 inhibition was not associated with significant changes in eGFR in patients with type 2 diabetes, likely resulting from a mixture of an initial reduction of eGFR and long-term renal function preservation. SGLT2 inhibition was associated with statistically significant albuminuria reduction in type 2 diabetic patients with CKD. |
format | Online Article Text |
id | pubmed-5490461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54904612017-06-29 Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis Xu, Lubin Li, Yang Lang, Jiaxin Xia, Peng Zhao, Xinyu Wang, Li Yu, Yang Chen, Limeng PeerJ Diabetes and Endocrinology AIM: To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes. METHODS: We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model. RESULTS: Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), −0.33 ml/min per 1.73 m(2), 95% CI [−0.90 to 0.23]) or in patients with chronic kidney disease (CKD) (WMD −0.78 ml/min per 1.73 m(2), 95% CI [−2.52 to 0.97]). SGLT2 inhibition was associated with eGFR reduction in short-term trials (WMD −0.98 ml/min per 1.73 m(2), 95% CI [−1.42 to −0.54]), and with eGFR preservation in long-term trials (WMD 2.01 ml/min per 1.73 m(2), 95% CI [0.86 to 3.16]). Urine ACR reduction after SGLT2 inhibition was not statistically significant in type 2 diabetic patients in general (WMD −7.24 mg/g, 95% CI [−15.54 to 1.06]), but was significant in patients with CKD (WMD −107.35 mg/g, 95% CI [−192.53 to −22.18]). CONCLUSIONS: SGLT2 inhibition was not associated with significant changes in eGFR in patients with type 2 diabetes, likely resulting from a mixture of an initial reduction of eGFR and long-term renal function preservation. SGLT2 inhibition was associated with statistically significant albuminuria reduction in type 2 diabetic patients with CKD. PeerJ Inc. 2017-06-27 /pmc/articles/PMC5490461/ /pubmed/28663934 http://dx.doi.org/10.7717/peerj.3405 Text en ©2017 Xu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Diabetes and Endocrinology Xu, Lubin Li, Yang Lang, Jiaxin Xia, Peng Zhao, Xinyu Wang, Li Yu, Yang Chen, Limeng Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis |
title | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis |
title_full | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis |
title_fullStr | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis |
title_full_unstemmed | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis |
title_short | Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis |
title_sort | effects of sodium-glucose co-transporter 2 (sglt2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis |
topic | Diabetes and Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490461/ https://www.ncbi.nlm.nih.gov/pubmed/28663934 http://dx.doi.org/10.7717/peerj.3405 |
work_keys_str_mv | AT xulubin effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis AT liyang effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis AT langjiaxin effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis AT xiapeng effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis AT zhaoxinyu effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis AT wangli effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis AT yuyang effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis AT chenlimeng effectsofsodiumglucosecotransporter2sglt2inhibitiononrenalfunctionandalbuminuriainpatientswithtype2diabetesasystematicreviewandmetaanalysis |